No Difference in Risk of Major Adverse Cardiovascular Events and Venous Thromboembolic Events Between Patients With Psoriasis or Psoriatic Arthritis on Tumor Necrosis Factor Inhibitors, Interleukin-17
Number of reports per year, classification according to seriousness and type of adverse reactions in patients treated with biological agents in Colombia from 2014–2019.
Top 20 least sparse features. The top 20 least sparse multi-variate features per dataset and patient group (i.e., ADE positive and ADE negative patients). The feature names are encoded as Nomenclature
